Literature DB >> 30834499

Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis.

Patrick Martineau1,2, Vincent Finnerty3, Geneviève Giraldeau4, Sébastien Authier3, Francois Harel3, Matthieu Pelletier-Galarneau5,6.   

Abstract

BACKGROUND: Conventional nuclear imaging with bone-seeking radiopharmaceuticals has been shown to be a sensitive test for the detection of transthyretin cardiac amyloidosis (ATTR); however, to date, few data exist on the utility of 18F-sodium fluoride (NaF) positron emission tomography (PET) in subjects with cardiac amyloidosis (CA).
METHODS: Myocardial perfusion imaging and cardiac 18F-NaF PET/CT of 7 subjects with ATTR, four with light-chain CA (AL), and four controls were retrospectively reviewed. Qualitative interpretation and quantitative analyses with average left ventricular standardized uptake values (SUVmean) and target-to-background ratios (TBRmean) were performed.
RESULTS: Average TBRmean was significantly increased in subjects with ATTR (0.98 ± 0.09) compared to AL (0.85 ± 0.08, P = .026) and CTL (0.82 ± 0.07, P = .020), while SUVmean was not (P = .14). Receiver-operator characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.91, with a sensitivity/specificity of 75%/100% for TBRmean using a cutoff value of 0.89 for the diagnosis of ATTR. Qualitative interpretation resulted in a sensitivity/specificity of 57%/100% for ATTR.
CONCLUSIONS: While 18F-NaF PET/CT demonstrates good diagnostic accuracy for ATTR, particularly when using quantitative analysis, the low TBRmean values observed in ATTR indicate poor myocardial signal. 18F-NaF PET/CT is not yet ready for clinical use in CA until further comparison studies are performed with 99mTc-DPD/PYP.

Entities:  

Keywords:  ATTR; Cardiac amyloidosis; bone scintigraphy; positron emission tomography; sodium fluoride; transthyretin

Mesh:

Substances:

Year:  2019        PMID: 30834499     DOI: 10.1007/s12350-019-01675-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  12 in total

1.  Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique.

Authors:  Cesia Gallegos; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2017-03-29       Impact factor: 5.952

2.  How to image cardiac amyloidosis.

Authors:  Rodney H Falk; Candida C Quarta; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2014-05       Impact factor: 7.792

Review 3.  Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions.

Authors:  Sukhdeep Bhogal; Vatsal Ladia; Puja Sitwala; Emilie Cook; Kailash Bajaj; Vijay Ramu; Carl J Lavie; Timir K Paul
Journal:  Curr Probl Cardiol       Date:  2017-04-13       Impact factor: 5.200

4.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

5.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Authors:  Enrica Perugini; Pier Luigi Guidalotti; Fabrizio Salvi; Robin M T Cooke; Cinzia Pettinato; Letizia Riva; Ornella Leone; Mohsen Farsad; Paolo Ciliberti; Letizia Bacchi-Reggiani; Francesco Fallani; Angelo Branzi; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

6.  Transthyretin cardiac amyloidoses in older North Americans.

Authors:  Kumar Dharmarajan; Mathew S Maurer
Journal:  J Am Geriatr Soc       Date:  2012-02-13       Impact factor: 5.562

7.  Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.

Authors:  David F Hutt; Anne-Marie Quigley; Joanne Page; Margaret L Hall; Maria Burniston; Dorothea Gopaul; Thirusha Lane; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-06-16       Impact factor: 6.875

Review 8.  Cardiac amyloidosis: pathology, nomenclature, and typing.

Authors:  Joseph J Maleszewski
Journal:  Cardiovasc Pathol       Date:  2015-08-01       Impact factor: 2.185

9.  Quantification of myocardial blood flow with 82Rb dynamic PET imaging.

Authors:  Mireille Lortie; Rob S B Beanlands; Keiichiro Yoshinaga; Ran Klein; Jean N Dasilva; Robert A DeKemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-07       Impact factor: 9.236

10.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690

View more
  9 in total

1.  Diagnosing cardiac amyloidosis: A wealth of new possibilities with nuclear cardiac imaging.

Authors:  Renée P Bullock-Palmer
Journal:  J Nucl Cardiol       Date:  2019-05-13       Impact factor: 5.952

2.  Variability in bone-seeking tracers and imaging protocols for the diagnosis of cardiac amyloidosis: The more the merrier?

Authors:  Michal Weiler-Sagie; Simona Ben-Haim
Journal:  J Nucl Cardiol       Date:  2020-09-07       Impact factor: 5.952

Review 3.  The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine.

Authors:  Rudolf A Werner; James T Thackeray; Johanna Diekmann; Desiree Weiberg; Johann Bauersachs; Frank M Bengel
Journal:  J Nucl Med       Date:  2020-04-17       Impact factor: 11.082

4.  Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.

Authors:  Zhaoye Wu; Chunjing Yu
Journal:  BMC Cardiovasc Disord       Date:  2021-10-07       Impact factor: 2.298

Review 5.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2020: positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2021-06-08       Impact factor: 5.952

Review 6.  Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.

Authors:  Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 7.  Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis.

Authors:  Yiu Ming Khor; Sarah Cuddy; Rodney H Falk; Sharmila Dorbala
Journal:  Semin Nucl Med       Date:  2020-02-09       Impact factor: 4.802

8.  Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Olivier Gheysens; Mark Lubberink; Tanja Kero; Marc R Dweck; Gilbert Habib; Oliver Gaemperli; Antti Saraste; Alessia Gimelli; Panagiotis Georgoulias; Hein J Verberne; Jan Bucerius; Christoph Rischpler; Fabien Hyafil; Paola A Erba
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-12-01       Impact factor: 6.875

9.  18F-fluoride PET/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls.

Authors:  Jack P M Andrews; Maria Giovanni Trivieri; Russell Everett; Nicholas Spath; Gillian MacNaught; Alastair J Moss; Mhairi K Doris; Tania Pawade; Edwin J R van Beek; Christophe Lucatelli; David E Newby; Philip Robson; Zahi A Fayad; Marc R Dweck
Journal:  J Nucl Cardiol       Date:  2020-09-30       Impact factor: 5.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.